Compare BigBearai Holdings Inc (BBAI) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BigBearai Holdings Inc vs GSK plc — how do they compare? BigBearai Holdings Inc trades at $3.11 (market cap $1.48B), while GSK plc trades at $51.21 (market cap $101.55B). The key difference: GSK plc is far larger — about 68.6× BigBearai Holdings Inc's market cap, and GSK plc pays a 3.5% dividend while BigBearai Holdings Inc pays none. Which is the better fit depends on your goals.
| BBAI | GSK | |
|---|---|---|
Market Cap | $1.48B | $101.55B |
Sector | Technology | Health |
52-Week High | $8.91 | $61.18 |
52-Week Low | $3.05 | $36.20 |
Enterprise Value | $1.16B | $122.16B |
Dividend Yield | — | 3.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BBAI trades at $3.08, down 5.81% in the past 24 hours, with a bearish technical signal from moving averages. The company reported revenue of $127.67M in 2025 but a net loss of $293.91M, reflecting a negative net margin of -226.69%. Recent news highlights AI growth opportunities in defense and airport security, yet profitability challenges persist.
Outlook remains cautious due to ongoing losses and negative cash flow from operations. Investment opportunities include backlog growth and debt reduction, but risks include high SG&A expenses and reliance on government contracts. Analyst consensus is mixed with 75% hold ratings, indicating uncertainty about near-term performance.
GSK trades at $52.29, down 0.93% with neutral technical signals. The company shows strong fundamentals with Q1 2026 EPS beating expectations at $1.24 versus $1.16 forecast. Recent FDA approvals for Utebzi and positive Jemperli trial results highlight pipeline strength. Valuation metrics appear reasonable with P/E of 13.94 and ROE of 36.42%.
GSK presents a balanced investment case with solid profitability and promising drug pipeline offset by mixed analyst sentiment and competitive pressures. The stock offers income potential with 3.46% dividend yield but faces execution risks in drug development and market competition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BigBearai Holdings Inc
BigBearai Holdings Inc is a specialized provider of AI-driven decision intelligence solutions, primarily serving the U.S. defense, intelligence, and national security communities. It operationalizes complex data into actionable insights through its core modules—Observe, Orient, and Dominate—to support mission-critical operations and logistics.
Read more on BBAI →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
